More recently, additional studies have indicated that propranolol could enhance the sensitivity of gastric cancer cells to radiotherapy by inhibiting beta-adrenoceptors, NF-κB expression, and its downstream genes: VEGF, EGFR, and COX-2 (Liao et al., 2010, 2018). The gene discussed is NFKB1; the disease is gastric cancer.